The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KOD | +376.97% | -80.04% | -27.53% | +107% |
| S&P | +17.35% | +108.64% | +15.84% | +135% |
Kodiak's portfolio of candidate eye treatments centers on its innovative antibody biopolymer conjugate platform.
An analyst downgrade is weighing on the drugmaker's stock price today.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$6.54M | 2.1% |
| Market Cap | $196.81M | 59.4% |
| Market Cap / Employee | $1.81M | 0.0% |
| Employees | 109 | -1.8% |
| Net Income | -$54.31M | -20.4% |
| EBITDA | -$48.97M | -18.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $104.17M | -52.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $153.92M | -7.2% |
| Short Term Debt | $11.29M | 14.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.71% | -20.8% |
| Return On Invested Capital | -43.35% | -8.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.81M | -31.1% |
| Operating Free Cash Flow | -$34.67M | -30.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.64 | 2.82 | 0.98 | 1.81 | 253.22% |
| Price to Tangible Book Value | 0.64 | 2.82 | 0.98 | 1.81 | 253.22% |
| Enterprise Value to EBITDA | -2.83 | -13.32 | -3.50 | -5.27 | 171.78% |
| Return on Equity | -78.6% | -84.7% | -108.9% | -140.3% | 96.28% |
| Total Debt | $173.44M | $170.35M | $167.64M | $165.21M | -6.00% |
KOD earnings call for the period ending March 31, 2020.
KOD earnings call for the period ending September 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
